Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

AIMS: Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium‐glucose co‐transporter‐2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in patients with HF independent of the presence or ab...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ESC Heart Fail
Главные авторы: Hundertmark, Moritz J., Agbaje, Olorunsola F., Coleman, Ruth, George, Jyothis T., Grempler, Rolf, Holman, Rury R., Lamlum, Hanan, Lee, Jisoo, Milton, Joanne E., Niessen, Heiko G., Rider, Oliver, Rodgers, Christopher T., Valkovič, Ladislav, Wicks, Eleanor, Mahmod, Masliza, Neubauer, Stefan
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2021
Предметы:
Study Designs
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8318430/
https://ncbi.nlm.nih.gov/pubmed/33960149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.13406
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы